<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01477801</url>
  </required_header>
  <id_info>
    <org_study_id>MCV-MO-11-001</org_study_id>
    <secondary_id>2011-001726-14</secondary_id>
    <nct_id>NCT01477801</nct_id>
  </id_info>
  <brief_title>Effects of Cholecalciferol Supplementation in Patients With Chronic Heart Failure and LOw vITamind D Levels</brief_title>
  <acronym>ECSPLOIT -D</acronym>
  <official_title>Effects of Cholecalciferol Supplementation in Patients With Chronic Heart Failure and LOw vITamind D Levels. A Phase 2 Randomized Double Blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Unita' Sanitaria Locale Di Modena</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abiogen Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Unita' Sanitaria Locale Di Modena</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether cholecalciferol supplementation in patients
      with chronic heart failure and low vitamin D levels improves:

        1. performance at six minutes walking test

        2. echocardiographic parameters

        3. neurohormonal imbalance
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">September 2012</completion_date>
  <primary_completion_date type="Anticipated">July 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SIX MINUTE WALKING TEST DISTANCE</measure>
    <time_frame>six months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ECHOCARDIOGRAPHIC PARAMETERS</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NEUROHORMONAL CHANGES</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Heart Failure</condition>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>CHOLECALCIFEROL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHOLECALCIFEROL</intervention_name>
    <description>Standard guideline based therapy plus cholecalciferol:
Loading dose 300.000 U then 50.000 U every month for six months</description>
    <arm_group_label>CHOLECALCIFEROL</arm_group_label>
    <other_name>DIBASE (ABIOGEN PHARMA)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <description>Standard guideline based therapy plus placebo</description>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Heart failure diagnosis according to European Society of Cardiology Guideline criteria

          -  Age &gt; 60 years old

          -  25(OH) Vitamin D level &lt; 30 ng/ml

          -  Clinical and therapeutic stability for one month (NYHA class II or III)

        Exclusion Criteria:

          -  Chronic use of anticonvulsants or barbiturates, steroids, thiazides, aluminium or
             magnesium, colestipol or cholestyramine

          -  Glomerular filtration rate lower than 30 ml/min/1.73 m2 according to MDRD equation

          -  Nephrolitiasis, Sarcoidosis or hypercalcemia

          -  Recent (three months) acute coronary syndrome or stroke or major vascular surgery

          -  Reduced life expectancy due to other diseases (active neoplasms, liver cirrhosis...)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabrizio Turrini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda USL di Modena</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marco Bondi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Azienda USL di Modena</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paola Loria, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Universit√† di Modena</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabrizio Turrini, MD</last_name>
    <phone>0039593961100</phone>
    <email>f.turrini@ausl.mo.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medicina Cardiovascolare - NOCSAE - Azienda USL</name>
      <address>
        <city>Modena</city>
        <state>(mo)</state>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrizio Turrini, MD</last_name>
      <phone>0039593961100</phone>
      <email>f.turrini@ausl.mo.it</email>
    </contact>
    <investigator>
      <last_name>Stefania Scarlini</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2011</study_first_submitted>
  <study_first_submitted_qc>November 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2011</study_first_posted>
  <last_update_submitted>November 18, 2011</last_update_submitted>
  <last_update_submitted_qc>November 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Unita' Sanitaria Locale Di Modena</investigator_affiliation>
    <investigator_full_name>TURRINI FABRIZIO</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

